

Supplemental Material

Supplemental Table 1. Results for all parameters in adjusted models assessing the association between gene expression and CRP and IL6 levels

Dependent Variable: CRP	ALOX5		CD163		CRP		ICAM1		IFIT1		IL6		NFKB1		NFKBIA		PTGER2		S100A9		SELENBP1		SIRPA		TLR2		TLR4		TNFRSF1B			
	coef.	p-value	coef.	p-value	coef.	p-value	coef.	p-value	coef.	p-value	coef.	p-value	coef.	p-value	coef.	p-value	coef.	p-value	coef.	p-value	coef.	p-value	coef.	p-value	coef.	p-value	coef.	p-value	coef.	p-value		
dCI*	0.020±0.008	p=0.0110	0.018±0.008	p=0.0248	-0.012±0.006	p=0.0525	0.010±0.008	p=0.1954	0.008±0.007	p=0.2371	-0.009±0.007	p=0.2036	0.020±0.008	p=0.0129	0.005±0.007	p=0.4637	0.022±0.008	p=0.0059	0.029±0.008	p=0.0001	0.022±0.007	p=0.0026	0.011±0.007	p=0.1296	0.012±0.007	p=0.0626	0.019±0.008	p=0.0196	0.022±0.008	p=0.0043		
Age, y	-0.015±0.003	p<0.0001	-0.014±0.003	p<0.0001	-0.014±0.003	p<0.0001	-0.014±0.003	p<0.0001	-0.014±0.003	p<0.0001	-0.014±0.003	p<0.0001	-0.015±0.003	p<0.0001	-0.015±0.003	p<0.0001	-0.014±0.003	p<0.0001	-0.014±0.003	p<0.0001	-0.015±0.003	p<0.0001	-0.014±0.003	p<0.0001	-0.014±0.003	p<0.0001	-0.014±0.003	p<0.0001	-0.014±0.003	p<0.0001		
Male sex	-0.134±0.045	p=0.0032	-0.139±0.045	p=0.0022	-0.134±0.046	p=0.0032	-0.139±0.046	p=0.0023	-0.141±0.045	p=0.0020	-0.143±0.045	p=0.0017	-0.129±0.046	p=0.0049	-0.140±0.046	p=0.0021	-0.126±0.046	p=0.0058	-0.139±0.045	p=0.0021	-0.128±0.046	p=0.0050	-0.140±0.045	p=0.0021	-0.139±0.045	p=0.0025	-0.142±0.045	p=0.0018	-0.133±0.045	p=0.0036		
Body mass index	-0.067±0.004	p<0.0001	-0.067±0.004	p<0.0001	-0.067±0.004	p<0.0001	-0.067±0.004	p<0.0001	-0.067±0.004	p<0.0001	-0.068±0.004	p<0.0001	-0.067±0.004	p<0.0001	-0.068±0.004	p<0.0001	-0.066±0.004	p<0.0001	-0.066±0.004	p<0.0001	-0.066±0.004	p<0.0001	-0.068±0.004	p<0.0001	-0.067±0.004	p<0.0001	-0.067±0.004	p<0.0001	-0.067±0.004	p<0.0001		
Diabetes	0.073±0.064	p=0.2555	0.073±0.064	p=0.2564	0.071±0.064	p=0.2679	0.074±0.064	p=0.2491	0.073±0.064	p=0.2592	0.070±0.064	p=0.2741	0.074±0.064	p=0.2516	0.072±0.064	p=0.2534	0.071±0.064	p=0.2584	0.076±0.064	p=0.2383	0.079±0.064	p=0.2184	0.076±0.064	p=0.2383	0.075±0.064	p=0.2438	0.076±0.064	p=0.2373	0.075±0.064	p=0.2457		
Total cholesterol : HDL	-0.085±0.027	p=0.0018	-0.086±0.027	p=0.0014	-0.083±0.027	p=0.0023	-0.085±0.027	p=0.0018	-0.085±0.027	p=0.0017	-0.084±0.027	p=0.0020	-0.085±0.027	p=0.0017	-0.085±0.027	p=0.0017	-0.085±0.027	p=0.0017	-0.087±0.027	p=0.0013	-0.088±0.027	p=0.0012	-0.085±0.027	p=0.0017	-0.085±0.027	p=0.0018	-0.086±0.027	p=0.0016	-0.085±0.027	p=0.0017		
Triglyceride	-0.000±0.000	p=0.6156	-0.000±0.000	p=0.6175	-0.000±0.000	p=0.6573	-0.000±0.000	p=0.6133	-0.000±0.000	p=0.6285	-0.000±0.000	p=0.6593	-0.000±0.000	p=0.6404	-0.000±0.000	p=0.6461	-0.000±0.000	p=0.6461	-0.000±0.000	p=0.6269	-0.000±0.000	p=0.7531	-0.000±0.000	p=0.6353	-0.000±0.000	p=0.6034	-0.000±0.000	p=0.6442	-0.000±0.000	p=0.6141		
Systolic blood pressure	-0.002±0.002	p=0.2974	-0.002±0.002	p=0.2910	-0.002±0.002	p=0.2492	-0.002±0.002	p=0.2855	-0.002±0.002	p=0.2672	-0.002±0.002	p=0.2528	-0.002±0.002	p=0.2973	-0.002±0.002	p=0.2777	-0.002±0.002	p=0.2908	-0.002±0.002	p=0.3214	-0.001±0.002	p=0.3504	-0.002±0.002	p=0.2951	-0.002±0.002	p=0.2852	-0.002±0.002	p=0.3021	-0.002±0.002	p=0.3112		
Diastolic blood pressure	0.001±0.003	p=0.6406	0.001±0.003	p=0.6185	0.001±0.003	p=0.6188	0.001±0.003	p=0.6044	0.001±0.003	p=0.6073	0.001±0.003	p=0.6039	0.001±0.003	p=0.6421	0.001±0.003	p=0.6121	0.001±0.003	p=0.6423	0.001±0.003	p=0.6446	0.001±0.003	p=0.7195	0.001±0.003	p=0.6293	0.001±0.003	p=0.6157	0.001±0.003	p=0.6089	0.001±0.003	p=0.6541		
Prevalent CHD	0.206±0.073	p=0.0046	0.201±0.073	p=0.0059	0.203±0.073	p=0.0052	0.202±0.073	p=0.0055	0.201±0.073	p=0.0058	0.201±0.073	p=0.0057	0.205±0.073	p=0.0049	0.203±0.073	p=0.0053	0.203±0.073	p=0.0052	0.206±0.073	p=0.0044	0.206±0.073	p=0.0046	0.205±0.073	p=0.0050	0.204±0.073	p=0.0050	0.205±0.073	p=0.0049	0.204±0.073	p=0.0051		
Smoker	-0.370±0.078	p<0.0001	-0.370±0.078	p<0.0001	-0.371±0.078	p<0.0001	-0.376±0.078	p<0.0001	-0.372±0.078	p<0.0001	-0.371±0.078	p<0.0001	-0.371±0.078	p<0.0001	-0.374±0.078	p<0.0001	-0.372±0.078	p<0.0001	-0.362±0.078	p<0.0001	-0.362±0.078	p<0.0001	-0.374±0.078	p<0.0001	-0.373±0.078	p<0.0001	-0.372±0.078	p<0.0001	-0.375±0.078	p<0.0001		
Current hormone replacement	-0.317±0.091	p=0.0005	-0.316±0.091	p=0.0005	-0.332±0.091	p=0.0003	-0.321±0.091	p=0.0005	-0.320±0.091	p=0.0005	-0.328±0.091	p=0.0003	-0.320±0.091	p=0.0005	-0.324±0.091	p=0.0004	-0.314±0.091	p=0.0006	-0.311±0.091	p=0.0007	-0.316±0.091	p=0.0005	-0.325±0.091	p=0.0005	-0.321±0.091	p=0.0005	-0.317±0.091	p=0.0005	-0.317±0.091	p=0.0005		
Anthypertensive Therapy	-0.142±0.048	p=0.0031	-0.139±0.048	p=0.0039	-0.145±0.048	p=0.0025	-0.142±0.048	p=0.0031	-0.140±0.048	p=0.0036	-0.145±0.048	p=0.0025	-0.140±0.048	p=0.0034	-0.143±0.048	p=0.0029	-0.139±0.048	p=0.0037	-0.138±0.048	p=0.0038	-0.146±0.048	p=0.0023	-0.141±0.048	p=0.0034	-0.141±0.048	p=0.0034	-0.141±0.048	p=0.0033	-0.140±0.048	p=0.0033		
Aspirin within 3 weeks	0.135±0.046	p=0.0033	0.133±0.046	p=0.0036	0.129±0.046	p=0.0049	0.133±0.046	p=0.0037	0.132±0.046	p=0.0042	0.130±0.046	p=0.0046	0.135±0.046	p=0.0038	0.134±0.046	p=0.0038	0.134±0.046	p=0.0038	0.135±0.046	p=0.0032	0.136±0.046	p=0.0030	0.134±0.046	p=0.0036	0.133±0.046	p=0.0038	0.132±0.046	p=0.0038	0.132±0.046	p=0.0039	0.134±0.046	p=0.0035
Lipid treatment	0.145±0.048	p=0.0026	0.142±0.048	p=0.0033	0.153±0.048	p=0.0015	0.146±0.048	p=0.0025	0.145±0.048	p=0.0026	0.151±0.048	p=0.0018	0.145±0.048	p=0.0026	0.145±0.048	p=0.0028	0.145±0.048	p=0.0028	0.142±0.048	p=0.0032	0.142±0.048	p=0.0032	0.146±0.048	p=0.0017	0.143±0.048	p=0.0032	0.146±0.048	p=0.0025	0.142±0.048	p=0.0034	0.146±0.048	p=0.0024

* Each regression model fitted the CRP or IL6 serum levels as the dependent variable with the listed independent variables. Separate models were fitted for each gene expression value and each biomarker. The row labeled dCI contains the regression coefficient gene labeling that column. These values (the association between gene expression and biomarker value) are listed in Table 2 of the published report.

Supplemental Table II. Association between CRP of IL6 and gene expression adjusting for other factors associated with body mass or adipocytokines

Dependent Variable: CRP	Circulating biomarkers associated with body mass or adipocytokines included as covariates				
	Baseline Model	ICAM1	MCP1	PSELECTIN	TNFR
	coef.±s.e., p-value	coef.±s.e., p-value	coef.±s.e., p-value	coef.±s.e., p-value	coef.±s.e., p-value
ALOX5	0.020±0.008, p=0.0110	0.037±0.017, p=0.0261	0.040±0.017, p=0.0171	0.040±0.017, p=0.0180	0.036±0.017, p=0.0329
CD163	0.018±0.008, p=0.0248	0.036±0.016, p=0.0285	0.038±0.017, p=0.0236	0.038±0.017, p=0.0232	0.037±0.016, p=0.0247
CRP	-0.012±0.006, p=0.0525	-0.012±0.013, p=0.3340	-0.018±0.013, p=0.1776	-0.017±0.013, p=0.2001	-0.016±0.013, p=0.2037
ICAM1	0.010±0.008, p=0.1954	0.020±0.016, p=0.2043	0.020±0.016, p=0.2240	0.020±0.016, p=0.2221	0.015±0.016, p=0.3451
IFIT1	0.008±0.007, p=0.2371	0.013±0.015, p=0.3672	0.015±0.015, p=0.3306	0.014±0.015, p=0.3312	0.012±0.015, p=0.4350
IL6	-0.009±0.007, p=0.2036	-0.007±0.014, p=0.6449	-0.012±0.015, p=0.3996	-0.011±0.014, p=0.4449	-0.012±0.014, p=0.3920
NFKB1	0.020±0.008, p=0.0129	0.038±0.017, p=0.0262	0.038±0.017, p=0.0285	0.039±0.017, p=0.0236	0.036±0.017, p=0.0370
NFKBIA	0.005±0.007, p=0.4637	0.017±0.015, p=0.2794	0.014±0.016, p=0.3630	0.017±0.016, p=0.2830	0.013±0.015, p=0.3821
PTGER2	0.022±0.008, p=0.0059	0.037±0.016, p=0.0228	0.036±0.017, p=0.0286	0.037±0.017, p=0.0250	0.036±0.016, p=0.0296
S100A9	0.029±0.008, p=0.0001	0.057±0.016, p=0.0004	0.063±0.016, p=0.0001	0.062±0.016, p=0.0002	0.058±0.016, p=0.0003
SELENBP1	0.022±0.007, p=0.0026	0.026±0.015, p=0.0891	0.032±0.015, p=0.0357	0.034±0.015, p=0.0240	0.025±0.015, p=0.1003
SIRPA	0.011±0.007, p=0.1296	0.025±0.015, p=0.0818	0.025±0.015, p=0.0952	0.025±0.015, p=0.0888	0.022±0.015, p=0.1305
TLR2	0.012±0.007, p=0.0626	0.025±0.014, p=0.0765	0.026±0.014, p=0.0710	0.025±0.014, p=0.0725	0.021±0.014, p=0.1363
TLR4	0.019±0.008, p=0.0196	0.042±0.017, p=0.0165	0.045±0.018, p=0.0102	0.044±0.017, p=0.0117	0.038±0.017, p=0.0281
TNFRSF1B	0.022±0.008, p=0.0043	0.036±0.016, p=0.0228	0.039±0.016, p=0.0163	0.039±0.016, p=0.0160	0.035±0.016, p=0.0315
Dependent Variable: IL6	Circulating biomarkers associated with body mass or adipocytokines included as covariates				
	Baseline Model	ICAM1	MCP1	PSELECTIN	TNFR
	coef.±s.e., p-value	coef.±s.e., p-value	coef.±s.e., p-value	coef.±s.e., p-value	coef.±s.e., p-value
ALOX5	0.012±0.005, p=0.0142	0.023±0.013, p=0.0779	0.024±0.013, p=0.0628	0.024±0.013, p=0.0628	0.019±0.013, p=0.1320
CD163	0.008±0.005, p=0.1091	0.011±0.013, p=0.4028	0.012±0.013, p=0.3325	0.012±0.013, p=0.3702	0.011±0.013, p=0.3634
CRP	-0.009±0.004, p=0.0121	-0.015±0.010, p=0.1226	-0.015±0.010, p=0.1290	-0.017±0.010, p=0.0935	-0.017±0.010, p=0.0770
ICAM1	0.009±0.005, p=0.0603	0.022±0.013, p=0.0758	0.022±0.013, p=0.0791	0.022±0.013, p=0.0789	0.017±0.012, p=0.1752
IFIT1	0.008±0.004, p=0.0621	0.017±0.011, p=0.1413	0.018±0.011, p=0.1074	0.017±0.012, p=0.1289	0.014±0.011, p=0.2047
IL6	-0.006±0.004, p=0.1490	-0.007±0.011, p=0.5594	-0.007±0.011, p=0.5296	-0.008±0.011, p=0.4699	-0.010±0.011, p=0.3546
NFKB1	0.010±0.005, p=0.0500	0.020±0.013, p=0.1402	0.019±0.013, p=0.1606	0.020±0.013, p=0.1267	0.017±0.013, p=0.2080
NFKBIA	0.006±0.005, p=0.2179	0.011±0.012, p=0.3576	0.007±0.012, p=0.5352	0.011±0.012, p=0.3432	0.007±0.012, p=0.5430
PTGER2	0.012±0.005, p=0.0121	0.022±0.013, p=0.0807	0.020±0.013, p=0.1197	0.022±0.013, p=0.0860	0.021±0.013, p=0.1009
S100A9	0.020±0.005, p<0.0001	0.040±0.013, p=0.0013	0.044±0.012, p=0.0005	0.042±0.013, p=0.0008	0.037±0.012, p=0.0026
SELENBP1	0.013±0.004, p=0.0033	0.025±0.012, p=0.0317	0.027±0.012, p=0.0226	0.031±0.012, p=0.0088	0.021±0.012, p=0.0708
SIRPA	0.006±0.004, p=0.1326	0.012±0.011, p=0.3092	0.010±0.011, p=0.3609	0.011±0.011, p=0.3210	0.009±0.011, p=0.4482
TLR2	0.011±0.004, p=0.0059	0.027±0.011, p=0.0150	0.028±0.011, p=0.0110	0.027±0.011, p=0.0146	0.021±0.011, p=0.0472
TLR4	0.017±0.005, p=0.0008	0.035±0.013, p=0.0095	0.037±0.013, p=0.0064	0.036±0.014, p=0.0075	0.029±0.013, p=0.0283
TNFRSF1B	0.012±0.005, p=0.0091	0.022±0.012, p=0.0823	0.022±0.012, p=0.0761	0.023±0.012, p=0.0659	0.018±0.012, p=0.1467

Coefficients refer the relationship between gene expression values indicated in each row and either IL6 or CRP levels as indicated. The "Baseline Model" is the model tabulated (in full) for Supplemental Table 1 and (in part) in Table 2 if the published report. Coefficients listed in the subsequent 5 columns also refer to the gene expression - biomarker level associations (adjusted for all previous covariates) but with the addition of other available cytokines.

Supplemental Table III.**A. Mouse Megakaryocytes Treated with CRP (Δ Ct Values)**

	Control	0.2 μ g/mL	2 μ g/mL	20 μ g/mL
<i>ALOX5</i>	5.2 \pm 0.8	5.0 \pm 1.1, $p=0.888$	6.4 \pm 1.2, $p=0.435$	5.7 \pm 1.3, $p=0.770$
<i>ICAM1</i>	12.0 \pm 0.8	7.9 \pm 0.9, $p=0.007$	7.7 \pm 0.8, $p=0.005$	8.8 \pm 0.8, $p=0.023$
<i>IFIT1</i>	11.6 \pm 0.6	10.1 \pm 0.7, $p=0.123$	-	11.5 \pm 0.5, $p=0.937$
<i>IL-6</i>	8.1 \pm 0.2	8.3 \pm 0.2, $p=0.673$	6.6 \pm 0.1, $p<0.001$	8.9 \pm 0.1, $p=0.020$
<i>NFKB1</i>	9.3 \pm 0.4	9.1 \pm 0.9, $p=0.862$	10.9 \pm 1.0, $p=0.096$	8.7 \pm 0.5, $p=0.550$
<i>NFKBIA</i>	5.6 \pm 0.3	2.4 \pm 0.1, $p<0.001$	0.6 \pm 0.1, $p<0.001$	3.7 \pm 0.1, $p<0.001$
<i>PTGER2</i>	10.4 \pm 0.5	9.8 \pm 0.1, $p=0.366$	8.0 \pm 0.3, $p=0.003$	9.8 \pm 0.2, $p=0.333$
<i>S100A9</i>	5.0 \pm 1.3	1.8 \pm 0.5, $p=0.058$	5.9 \pm 0.5, $p=0.575$	4.4 \pm 0.4, $p=0.683$
<i>SELENBP1</i>	9.5 \pm 0.2	9.6 \pm 0.3, $p=0.701$	7.8 \pm 0.3, $p<0.001$	8.7 \pm 0.3, $p=0.024$
<i>SIRPA</i>	5.5 \pm 0.4	7.4 \pm 1.1, $p=0.378$	3.2 \pm 0.0, $p=0.428$	17.5 \pm 2.3, $p=0.005$
<i>TLR2</i>	11.6 \pm 0.3	13.0 \pm 0.3, $p=0.074$	8.2 \pm 0.9, $p<0.001$	11.6 \pm 0.6, $p=0.970$
<i>TLR4</i>	9.7 \pm 0.3	9.4 \pm 0.3, $p=0.553$	10.1 \pm 0.7, $p=0.530$	10.1 \pm 0.3, $p=0.422$
<i>TNFRSF1B</i>	8.4 \pm 0.2	8.3 \pm 0.5, $p=0.794$	9.6 \pm 0.3, $p=0.018$	9.6 \pm 0.4, $p=0.014$

B. Mouse Megakaryocytes Treated with IL-6 (Δ CT Values)

	Control	1 μ g/mL	10 μ g/mL	100 μ g/mL
<i>ALOX5</i>	5.2 \pm 0.8	5.1 \pm 1.2, $p=0.938$	4.8 \pm 1.2, $p=0.750$	-
<i>ICAM1</i>	12.0 \pm 0.8	12.4 \pm 1.2, $p=0.791$	9.6 \pm 0.9, $p=0.116$	-
<i>IFIT1</i>	11.6 \pm 0.6	11.7 \pm 0.4, $p=0.844$	15.0 \pm 0.7, $p=0.003$	-
<i>IL-6</i>	8.1 \pm 0.2	8.5 \pm 0.2, $p=0.352$	8.1 \pm 0.2, $p=0.906$	-
<i>NFKB1</i>	9.3 \pm 0.4	9.2 \pm 0.6, $p=0.961$	9.0 \pm 0.6, $p=0.647$	-
<i>NFKBIA</i>	5.6 \pm 0.3	4.6 \pm 0.1, $p=0.021$	3.6 \pm 0.0, $p<0.001$	3.8 \pm 0.4, $p=0.001$
<i>PTGER2</i>	10.4 \pm 0.5	9.6 \pm 0.1, $p=0.297$	9.1 \pm 0.2, $p=0.097$	-
<i>S100A9</i>	5.0 \pm 1.3	8.8 \pm 0.5, $p=0.030$	2.5 \pm 0.3, $p=0.122$	0.4 \pm 0.2, $p=0.011$
<i>SELENBP1</i>	9.5 \pm 0.2	9.8 \pm 0.1, $p=0.200$	9.0 \pm 0.1, $p=0.032$	-
<i>SIRPA</i>	5.5 \pm 0.4	11.1 \pm 4.4, $p=0.176$	6.7 \pm 1.2, $p=0.703$	-
<i>TLR2</i>	11.6 \pm 0.3	12.0 \pm 0.2, $p=0.485$	11.0 \pm 0.3, $p=0.210$	2.3 \pm 0.5, $p<0.001$
<i>TLR4</i>	9.7 \pm 0.3	10.1 \pm 0.4, $p=0.387$	9.5 \pm 0.2, $p=0.639$	-
<i>TNFRSF1B</i>	8.4 \pm 0.2	8.2 \pm 0.1, $p=0.570$	8.4 \pm 0.3, $p=0.961$	-

p -values represent comparison to controls

Supplemental Table IV.**A. Human Platelets Treated with CRP (Δ Ct Values)**

	Control	0.2 μ g/mL	2 μ g/mL	20 μ g/mL
<i>ALOX5</i>	9.4 \pm 0.3	8.2 \pm 0.4, <i>p</i> =0.076	9.1 \pm 0.3, <i>p</i> =0.697	8.7 \pm 0.6, <i>p</i> =0.132
<i>CD163</i>	11.7 \pm 0.5	12.1 \pm 1.0, <i>p</i> =0.609	11.4 \pm 1.0, <i>p</i> =0.825	11.2 \pm 1.3, <i>p</i> =0.666
<i>CRP</i>	15.3 \pm 1.1	14.7 \pm 1.4, <i>p</i> =0.804	13.6 \pm 1.8, <i>p</i> =0.341	15.9 \pm 2.0, <i>p</i> =0.667
<i>ICAM1</i>	14.2 \pm 0.8	13.2 \pm 1.1, <i>p</i> =0.527	13.1 \pm 1.5, <i>p</i> =0.491	14.2 \pm 1.4, <i>p</i> =0.938
<i>IFIT1</i>	11.0 \pm 0.5	10.4 \pm 0.1, <i>p</i> =0.182	9.9 \pm 0.5, <i>p</i> =0.046	10.7 \pm 0.4, <i>p</i> =0.651
<i>IL-6</i>	14.3 \pm 1.5	14.1 \pm 1.3, <i>p</i> =0.914	11.4 \pm 1.9, <i>p</i> =0.211	13.4 \pm 2.2, <i>p</i> =0.726
<i>NFKB1</i>	9.3 \pm 0.5	9.1 \pm 0.4, <i>p</i> =0.943	8.8 \pm 0.5, <i>p</i> =0.742	9.3 \pm 0.5, <i>p</i> =0.962
<i>NFKBIA</i>	7.7 \pm 0.4	7.4 \pm 0.5, <i>p</i> =0.822	8.0 \pm 0.5, <i>p</i> =0.503	8.6 \pm 0.6, <i>p</i> =0.124
<i>PTGER2</i>	10.8 \pm 0.3	10.4 \pm 0.5, <i>p</i> =0.581	10.1 \pm 0.4, <i>p</i> =0.230	10.6 \pm 0.2, <i>p</i> =0.867
<i>S100A9</i>	4.7 \pm 0.4	4.4 \pm 0.4, <i>p</i> =0.712	4.3 \pm 0.4, <i>p</i> =0.673	5.2 \pm 0.3, <i>p</i> =0.469
<i>SELENBP1</i>	12.5 \pm 0.6	12.4 \pm 0.8, <i>p</i> =0.883	12.3 \pm 1.1, <i>p</i> =0.977	12.2 \pm 0.7, <i>p</i> =0.684
<i>SIRPA</i>	11.5 \pm 0.5	11.3 \pm 0.9, <i>p</i> =0.841	11.9 \pm 1.4, <i>p</i> =0.665	11.0 \pm 0.6, <i>p</i> =0.673
<i>TLR2</i>	11.5 \pm 0.8	11.0 \pm 0.6, <i>p</i> =0.608	10.4 \pm 0.8, <i>p</i> =0.291	12.1 \pm 0.7, <i>p</i> =0.280
<i>TLR4</i>	12.4 \pm 0.5	12.0 \pm 0.7, <i>p</i> =0.660	12.5 \pm 1.3, <i>p</i> =0.955	12.6 \pm 0.8, <i>p</i> =0.929
<i>TNFRSF1B</i>	12.8 \pm 0.6	12.2 \pm 0.7, <i>p</i> =0.456	11.5 \pm 0.9, <i>p</i> =0.219	11.6 \pm 0.6, <i>p</i> =0.441

B. Human Platelets Treated with IL-6 (Δ Ct Values)

	Control	1 μ g/mL	10 μ g/mL	100 μ g/mL
<i>ALOX5</i>	9.4 \pm 0.3	8.9 \pm 0.6, <i>p</i> =0.536	8.6 \pm 0.4, <i>p</i> =0.307	8.1 \pm 0.7, <i>p</i> =0.078
<i>CD163</i>	11.7 \pm 0.5	11.5 \pm 1.8, <i>p</i> =0.931	11.0 \pm 0.6, <i>p</i> =0.687	11.5 \pm 1.9, <i>p</i> =0.980
<i>CRP</i>	15.3 \pm 1.1	13.2 \pm 1.6, <i>p</i> =0.402	13.1 \pm 1.6, <i>p</i> =0.374	12.2 \pm 2.1, <i>p</i> =0.213
<i>ICAM1</i>	14.2 \pm 0.8	12.1 \pm 1.1, <i>p</i> =0.299	12.4 \pm 1.2, <i>p</i> =0.369	11.4 \pm 2.0, <i>p</i> =0.166
<i>IFIT1</i>	11.0 \pm 0.5	10.5 \pm 1.5, <i>p</i> =0.631	10.1 \pm 0.8, <i>p</i> =0.419	9.4 \pm 1.0, <i>p</i> =0.193
<i>IL-6</i>	10.3 \pm 0.5	9.8 \pm 0.9, <i>p</i> =0.744	9.6 \pm 0.7, <i>p</i> =0.623	8.6 \pm 0.9, <i>p</i> =0.081
<i>NFKB1</i>	14.3 \pm 1.5	11.0 \pm 1.5, <i>p</i> =0.166	12.4 \pm 1.2, <i>p</i> =0.416	11.7 \pm 1.9, <i>p</i> =0.264
<i>NFKBIA</i>	9.3 \pm 0.5	9.1 \pm 0.8, <i>p</i> =0.984	9.4 \pm 0.6, <i>p</i> =0.756	7.9 \pm 0.7, <i>p</i> =0.209
<i>PTGER2</i>	7.7 \pm 0.4	7.2 \pm 0.5, <i>p</i> =0.664	8.9 \pm 0.9, <i>p</i> =0.155	7.2 \pm 0.6, <i>p</i> =0.709
<i>S100A9</i>	10.8 \pm 0.3	9.6 \pm 0.8, <i>p</i> =0.247	10.1 \pm 0.5, <i>p</i> =0.535	9.6 \pm 1.2, <i>p</i> =0.235
<i>SELENBP1</i>	4.7 \pm 0.4	3.7 \pm 0.3, <i>p</i> =0.122	3.9 \pm 0.2, <i>p</i> =0.223	4.5 \pm 0.4, <i>p</i> =0.935
<i>SIRPA</i>	12.5 \pm 0.6	11.3 \pm 0.9, <i>p</i> =0.498	11.8 \pm 1.1, <i>p</i> =0.729	10.6 \pm 1.4, <i>p</i> =0.241
<i>TLR2</i>	11.5 \pm 0.5	12.0 \pm 1.1, <i>p</i> =0.712	12.0 \pm 1.5, <i>p</i> =0.703	10.7 \pm 1.6, <i>p</i> =0.531
<i>TLR4</i>	11.5 \pm 0.8	11.4 \pm 0.8, <i>p</i> =0.901	10.0 \pm 1.2, <i>p</i> =0.348	10.7 \pm 1.6, <i>p</i> =0.584
<i>TNFRSF1B</i>	12.4 \pm 0.5	12.7 \pm 1.3, <i>p</i> =0.930	11.2 \pm 0.5, <i>p</i> =0.454	11.6 \pm 1.9, <i>p</i> =0.598
<i>ALOX5</i>	12.8 \pm 0.6	11.2 \pm 1.0, <i>p</i> =0.252	11.0 \pm 0.7, <i>p</i> =0.206	9.5 \pm 1.6, <i>p</i> =0.044

p-values represent comparison to controls

Supplemental Figure I




Figure Legend: (A) IgG controls for immunofluorescent staining of mouse megakaryocytes. (B) Fluorescence was determined using ImageJ. n=7 cells per conditions; compared to Control (with or without buffer). (C) Western blot analysis of platelets for TNFRSF1B, CD45 (immune cell marker), and Actin (loading control). (D) IgG controls for immunofluorescent staining of platelets.